Dimensional Fund Advisors
RGLS

Dimensional Fund Advisors’s Regulus Therapeutics RGLS Stock Holding History

Dimensional Fund Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$54K Buy
+31,618
New +$56.9K ﹤0.01% 3397
2017
Q1 		– Sell
-112
Closed -$30K – 3308
2016
Q4 		$30K Buy
+112
New +$36.4K ﹤0.01% 3282

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors's RGLS Position: Q3 2022 in Review

Dimensional Fund Advisors opened a new position in Regulus Therapeutics (RGLS) in Q3 2022: 31,618 shares worth $54K. The stake represents ﹤0.01% of the portfolio and ranks #3397 among its holdings. This is a return to the name: Dimensional Fund Advisors previously reported a position in RGLS as recently as Q4 2016.

Dimensional Fund Advisors first reported a position in RGLS in Q4 2016 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold RGLS as of Q3 2022.

  • Dimensional Fund Advisors held 31,618 shares of Regulus Therapeutics worth $54K as of Q3 2022.
  • Regulus Therapeutics was a new Dimensional Fund Advisors position in Q3 2022.
  • Regulus Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2022, its #3397 holding.
  • Dimensional Fund Advisors first reported a position in Regulus Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2022.

Based on Dimensional Fund Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.